Stock Quote Notification for Windtree Therapeutics, Inc

Windtreetx sent this email to their subscribers on December 13, 2024.

Company: Windtree Therapeutics, Inc
Ticker: WINT
Exchange: NASDAQ
Last Trade: $0.35
Change: -0.0066
% Change: -1.83%
Volume: 165,754
Day's High: $0.36
Day's Low: $0.34
Previous Close: $0.36

Text-only version of this email

Windtree Therapeutics, Inc Company: Windtree Therapeutics, Inc Ticker: WINT Exchange: NASDAQ Last Trade: $0.35 Change: -0.0066 % Change: -1.83% Volume: 165,754 Day's High: $0.36 Day's Low: $0.34 Previous Close: $0.36

Show all

The Latest Emails Sent By Windtreetx

Weekly Summary Alert for Windtree Therapeutics, Inc

Weekly Summary Alert for Windtree Therapeutics, Inc

Stock Quote Notification for Windtree Therapeutics, Inc

Stock Quote Notification for Windtree Therapeutics, Inc

Stock Quote Notification for Windtree Therapeutics, Inc

Stock Quote Notification for Windtree Therapeutics, Inc

Stock Quote Notification for Windtree Therapeutics, Inc

Stock Quote Notification for Windtree Therapeutics, Inc

Windtree Strengthens Global Intellectual Property Portfolio with New Japanese Patent For the Company’s Oncology Pipeline

Windtree Strengthens Global Intellectual Property Portfolio with New Japanese Patent For the Company’s Oncology Pipeline

Stock Quote Notification for Windtree Therapeutics, Inc

Stock Quote Notification for Windtree Therapeutics, Inc

More Emails, Deals & Coupons From Windtreetx

Windtree Announces Partnership with New Growth Advisors to Leverage Positive Phase 2 Istaroxime Study in Cardiogenic Shock for a Potential Strategic Transaction

Windtree Announces Partnership with New Growth Advisors to Leverage Positive Phase 2 Istaroxime Study in Cardiogenic Shock for a Potential Strategic Transaction

Stock Quote Notification for Windtree Therapeutics, Inc

Stock Quote Notification for Windtree Therapeutics, Inc

New Form 8-K/A for Windtree Therapeutics, Inc

New Form 8-K/A for Windtree Therapeutics, Inc

Stock Quote Notification for Windtree Therapeutics, Inc

Stock Quote Notification for Windtree Therapeutics, Inc

Windtree Completes Enrollment of Phase 2b Study of Istaroxime in Early Cardiogenic Shock

Windtree Completes Enrollment of Phase 2b Study of Istaroxime in Early Cardiogenic Shock

Windtree Therapeutics Provides Update on Istaroxime Clinical Development and Upcoming Clinical Trial Data

Windtree Therapeutics Provides Update on Istaroxime Clinical Development and Upcoming Clinical Trial Data

Stock Quote Notification for Windtree Therapeutics, Inc

Stock Quote Notification for Windtree Therapeutics, Inc

New Form 8-K for Windtree Therapeutics, Inc

New Form 8-K for Windtree Therapeutics, Inc

New Form PRE 14A for Windtree Therapeutics, Inc

New Form PRE 14A for Windtree Therapeutics, Inc

Stock Quote Notification for Windtree Therapeutics, Inc

Stock Quote Notification for Windtree Therapeutics, Inc

Windtree Announces Leadership Transition Plan With Industry Veterans

Windtree Announces Leadership Transition Plan With Industry Veterans

Windtree Announces Positive Phase 2b Topline Clinical Results with Istaroxime Significantly Improving Cardiac Function and Blood Pressure in Heart Failure Patients in Early Cardiogenic Shock

Windtree Announces Positive Phase 2b Topline Clinical Results with Istaroxime Significantly Improving Cardiac Function and Blood Pressure in Heart Failure Patients in Early Cardiogenic Shock